BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: Focus on bioactivity

Recent Patents on CNS Drug Discovery

Volumn 6, Issue 2, 2011, Pages 91-106

  Evin, Genevieve ^a   Lessene, Guillaume ^b   Wilkins, Simon ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Secretase; A amyloid; Alzheimer's disease; Aspartyl protease; Preclinical trial; Protease inhibitor

Indexed keywords

1,3 DIAMINO 2 PROPANOL; AC 3; AMG 0683; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ATG Z 1; BETA SECRETASE 1; BETA SECRETASE 1 INHIBITOR; BETA SECRETASE INHIBITOR; BMS 782450; BMS 782457; CATHEPSIN D; CTS 21166; GRL 7234; GRL 8234; GSK 188909; GUANIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; JNJ 715754; LY 2811376; NB 216; NB 533; NB 544; PRESENILIN 1; PRESENILIN 2; PYRROLIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SCH 745966; SEMAGACESTAT; TAK 070; TC 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NEUROPATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; HUMANS; PATENTS AS TOPIC; PROTEASE INHIBITORS;

EID: 79959332152     PISSN: 15748898     EISSN: 15748898     Source Type: Journal    
DOI: 10.2174/157488911795933938     Document Type: Article

References (131)

1. Masters CL, Beyreuther K. Alzheimer's centennial legacy: Prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 2006; 129: 2823-39.
2. Tanzi R, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 2005; 120: 545-55.
3. Town T. Alternative Aβ immunotherapy approaches for Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8: 114-27.
4. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7: 779-86.
5. Willey J, Elkind, MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010; 67: 1062-7.
6. De Strooper B, Annaert W. Novel research horizons for presenilins and γ-secretases in cell biology and disease. Annu Rev Cell Dev Biol 2010: 235-60.
7. De Strooper B, Vassar R, Golde T. The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010; 6: 99-107.
8. Evin G, Weidemann A. Biogenesis and metabolism of Alzheimer's disease Aβ amyloid peptides. Peptides 2002; 23: 1285-97.
9. Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M, et al. EHT0202 in Alzheimer's Disease: A 3-Month, Randomized, Placebo-Controlled, Double-Blind Study. Curr Alzheimer Res 2011: Jan 11. [Epub ahead of print]; PMID: 21222604 [
10. Jorissen E, De Strooper B, Kopan R. γ-Secretase and the Intramembrane Proteolysis of Notch. Current Topics in Developmental Biology. Academic Press: 2010: 201-30.
11. Evin G. γ -Secretase modulators: hopes and setbacks for the future of Alzheimer's treatment. Expert Rev Neurother 2008; 8: 1611-3.
12. Luo Y, Bolon B, Kahn S, Bennett B, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β -amyloid generation. Nat Neurosci 2001; 4: 231-2.
13. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 2005; 280: 30797-806.
14. Hitt B, Jaramillo T, Chetkovich D, Vassar R. BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener 2010; 5: 31.
15. Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, et al. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci 2010; 30: 8819-29.
16. Evin G, Barakat A, Masters CL. BACE: Therapeutic target and potential biomarker for Alzheimer's disease. Int J Biochem Cell Biol 2010; 42: 1923-6.
17. Peng KA, Masliah E. Lentivirus-Expressed siRNA Vectors Against Alzheimer Disease. Methods in Molecular Biology 2010; 614: 215-24.
18. Singer O, Marr R, Rockenstein E, Crews L, Coufal N, Gage F, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005; 8: 1343-9.
19. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 2010; 30: 11157-66.
20. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β -cleavage of amyloid precursor protein and amyloid- β production in vivo. J Neurochem 2007; 100: 802-9.
21. Sankaranarayanan S, Price EA, Wu G, Crouthamel M-C, Shi X-P, Tugusheva K, et al. In vivo β -secretase 1 inhibition leads to brain Aβ lowering and increased β -secretase processing of Amyloid Precursor Protein without effect on Neuregulin-1. J Pharmacol Exp Ther 2008; 324: 957-69.
22. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni SS, Xu X, Chang W, et al. J Med Chem 2007; 50:2399-407.
23. Tang, J.J.N., Ghosh, A.K. Inhibitors of Memapsin 2 and use thereof. US7678760 (2010).
24. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh A, et al. Structure of the protease domain of memapsin 2 (β -secretase) complexed with inhibitor. Sci 2000; 290: 150-3.
25. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Xu X, Miller HB, et al. Potent memapsin 2 (β -secretase) inhibitors: Design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 2008; 18: 1031-6.
26. Ghosh, A.K., Kumaragurubaran, N., Liu, C., Devasamudram, T., Lei, H., Swanson, L,M., Ankala, S.V., Tang, J.J.N., Bilcer, G.M. Compounds which inhibit β -secretase activity and methods of use. US7504420 (2009).
27. Chang W-P, Huang X, Downs D, Cirrito J, Koelsch G, Holtzman DM, et al. β -Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 2010; 25: 775-784.
28. Bilcer, G.M., Devasamudram, T., Ankala, S.V., Lilly, J.C., Liu, C., Lei, H., Ghosh, A.K., Inoue, M. Pyrrolidine compounds which inhibit β -secretase activity and methods of use thereof. WO2010042892 (2010).
29. Zhong, W., Hitchcock, S., lbrecht, B.K., Bartberger, M.D., Brown, J., Brown, R., Chaffee, S.C., Cheng, Y., Croghan, M., Graceffa, R., Harried, S., Hitchcock, S., Hungate, R., Judd, T., Kaller, M., Kreiman, C., La, D., Lopez, P., Masse, C., Monenschein, H., Nguyen, T., Nixey, T., Patel, V.F., Pennington, L., Weiss, M., Yang, B., Zhong, W. β -Secretase modulators and methods of use. US20070185144 (2007).
30. Zhong, W., Hitchcock, S., Patel, V.F., Croghan M, Dineen T, Harried, S., Horne D, Judd, T., Kaller, M., Kreiman, C., Lopez, P., Monenschein, H., Nguyen, T., Weiss, M., Xue, Q., Yang, B. Substituted hydroxyethyl amine compounds as β -secretase modulators and methods of use. US20090036478 (2009).
31. Zhong, W., Hitchcock, S., Albrecht, B.K., Bartberger, M.D., Brown, J.M., Brown, R., Chaffee, S.C, Cheng, Y., Croghan, M., Graceffa, R., Harried, S., Hickman, D., Horne, D., Hunbgate R., Judd, T., Kaller, M., Kreiman, C., La, D., Lopez, P., Masse, C.E., Nixey, T., Patel, V.F., Pennington, L., Weiss, M., Xue, Q., Yang, B., Monenschein, H., Nguyen, T., β -secretase modulators and methods of use. US20100222338 (2010).
32. Graceffa, R., Kaller, M., La, D., Lopez, P., Patel, V.F., Zhong, W. Substituted pyrano [2,3-b] pyridinamine compounds as β -secretase modulators and methods of use. US20100120774 (2010).
33. Albrecht, B.K., Andersen, D.L., Bartberger M., Brown, J., Brown, R., Chaffee, S.C., Cheng, Y., Croghan, M., Graceffa, R., Harried, S., Hitchcock, S., Hunbgate, R., Judd, T., Kaller, M., Kreiman, C., La, D., Lopez, P., Masse, C.E., Monenschein, H., Nguyen, T., Nixey, T., Patel, V.F., Pennington, L., Weiss, M., Xue, Q., Yang, B., Zhong, W. β -secretase modulators and methods of use. US20070185103 (2007).
34. Marcin LR, Higgins MA, Zusi FC, Zhang Y, Dee MF, Parker MF, et al. Synthesis and SAR of indole-and 7-azaindole-1,3- dicarboxamide hydroxyethylamine inhibitors of BACE-1. Bioorg Med Chem Lett 2010; In Press, Accepted Manuscript.
35. Stachel S, Coburn C, Steele T, Jones K, Loutzenhiser E, Gregro A, et al. Structure-based design of potent and selective cell-permeable inhibitors of human β -secretase (BACE-1). J Med Chem 2004; 47: 6447-50.
36. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, et al. BACE1 inhibition reduces endogenous Aβ and alters APP processing in wild-type mice. J Neurochem 2006; 99: 1555-63.
37. Coburn, C.A., Nantermet, P.G., Rajapakse, H.A., Selnick, H.G., Stauffer, S.R. Aminomethyl β -secretase inhibitors for the treatment of Alzheimer's disease. US20080153846 (2008).
38. Coburn C, Stachel S, Jones K, Steele T, Rush D, DiMuzio JP, et al. BACE-1 inhibition by a series of psi[CH2NH] reduced amide isosteres. Bioorg Med Chem Lett 2006; 16: 3635-8.
39. Stachel S, Coburn C, Sankaranarayanan S, Price E, Wu G, Crouthamel M, et al. Macrocyclic inhibitors of β-secretase: functional activity in an animal model. J Med Chem 2006; 49: 6147-50.
40. Nantermet, P.G., Holloway, K.M., Moore, K.P., Stauffer, S.R. Macrocyclic spiropiperidine β-secretase inhibitors for the treatment of Alzheimer's disease. US20100029701 (2010).
41. Stauffer, S.R., Graham, S.L. Bicyclic spiropiperidine β-secretase inhibitors for the treatment of Alzheimer's disease. US20100076004 (2010).
42. Nantermet, P.G., Rajapakse, H.A., Selnick, H.G. Benzylether and benzyl amino β-secretase inhibitors for the treatment of Alzheimer's disease. US20100210693 (2010).
43. Eickmeier, C., Peters, S., Fuchs, K., Heine, N., Handschuh, S., Dorner-Ciossek, C., Klinder, K., Kostka, M. Substituted 1,2- ethylenediamines, methods for preparing them and uses thereof. US20107713961 (2010).
44. Marcin, L.R., Good, A.C. Macrocyclic diaminopropanes as β- secretase inhibitors. US20070037868 (2007).
45. Marcin, L.R., Good, A.C., Wu, Y.-J.Z., Dmitry, S., Olson, R.E., Wang, N. Diaminopropane derived macrocycles as inhibitors of β- amyloid production. US20107772221 (2010).
46. Gailunas, A., Tucker, J.A., Tenbrink, R., Mickelson, J. N-(3- amino-2-hydroxy-propyl)substituted alkylamide compounds. US20100048590 (2010).
47. John, V., Maillard, M., Beck, J.P., Baldwin, E.T., Hughes, R., Pulley, S.R., TenBrink, T. Acetyl 2-hydroxy-1.3-diaminoalkanes. US20100145056 (2010).
48. Maillard M, Hom R, Benson T, Moon J, Mamo S, Bienkowski M, et al. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human β- secretase. J Med Chem 2007; 50: 776-81.
49. Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, et al. Design and synthesis of cell potent BACE-1 inhibitors: Structureactivity relationship of P1' substituents. Bioorg Med Chem Lett 2009; 19: 6386-91.
50. Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, et al. Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structure-activity relationship of P2' substituents. Bioorg Med Chem Lett 2010; 20: 4789-94.
51. Truong AP, Tóth G, Probst GD, Sealy JM, Bowers S, Wone DWG, et al. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett 2010; 20: 6231-6.
52. Bueno-Melendo, A.B., Chen, S.-h., Erickson, J.A., Gonzalez-Garcia, M.R., Guo, D., Marcos-LLorente, A., Mccarthy, J.R., Sheperd, T.A., Sheehan, S.M., Yip, Y.Y.M. Amides as BACE inhibitors. WO2005108391 (2005).
53. Bueno-Melendo, A.B., Chen, S.-H., Gonzalez-Garcia, M.R., Mccarthy, J.R. Amides as BACE inhibitors. US20097618978 (2009).
54. Broughton, H.B., Dally, R.D., Durham, T.B., Gonzalez-Garcia, M.R., Hahn, P.J., Henry, Jr.K.J., Kohn, T.J., Mccarthy, J.R., Shepherd, T.A., Erickson, J.A., Bueno Melendo, A.B. 3-(2- acylamino-1-hydroxyethyl)-morpholine derivatives and their use as BACE inhibitors. US20107745438 (2010).
55. Machauer R, Laumen K, Veenstra S, Rondeau J-M, Tintelnot-Blomley M, Betschart C, et al. Macrocyclic peptidomimetic β- secretase (BACE-1) inhibitors with activity in vivo. Bioorg Med Chem Lett 2009; 19: 1366-70.
56. Laumen, K., Machauer, R., Tintelnot-Blomley, M., Veenstra, S.J. Macrocyclic compounds useful as BACE inhibitors. US20090312370 (2009).
57. Lerchner, A., Machauer, R., Tintelnot-Blomley, M., Simic, O. Macrocyclic compounds and compositions useful as BACE inhibitors. US20080214526 (2008).
58. Machauer, R. Macrocyclic compounds useful as BACE inhibitors. US20090170878 (2009).
59. Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, et al. Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application. Bioorg Med Chem Lett 2010; 20: 603-7.
60. Iserloh U, Pan J, Stamford AW, Kennedy ME, Zhang Q, Zhang L, et al. Discovery of an orally efficaceous 4-phenoxypyrrolidinebased BACE-1 inhibitor. Bioorg Med Chem Lett 2008; 18: 418-22.
61. Iserloh U, Wu Y, Cumming JN, Pan J, Wang LY, Stamford AW, et al. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg Med Chem Lett 2008; 18: 414-7.
62. Cumming, J.N., Iserloh, U., Stamford, A., Strickland, C., Voigt, J.H., Wu Y., Huang, Y., Xia, Y., Chackalamannil, S., Guo, T., Hobbs, D.W., Le, X., Thuy, H., Lowrie, J.F., Saionz, K.W., Babu, S.D. Cyclic amine BACE-1 inhibitors having a benzamide substituent. US20100152138 (2010).
63. Stamford, A.W., Zhu, Z., Mandal, M., Liu, X. Thiophenyl substituted 2-amino-3-methyl pyrrolopyrimidinone compounds as BACE-1 inhbitors, compositions and their use. WO2009131974 (2009).
64. Cumming JN, Le TX, Babu S, Carroll C, Chen X, Favreau L, et al. Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors. Bioorg Med Chem Lett 2008; 18: 3236-41.
65. Hanessian S, Shao Z, Betschart C, Rondeau JM, Neumann U, Tintelnot-Blomley M. Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors. Bioorg Med Chem Lett 2010; 20: 1924-7.
66. Clarke B, Demont E, Dingwall C, Dunsdon R, Faller A, Hawkins J, et al. BACE-1 inhibitors part 1: Identification of novel hydroxy ethylamines (HEAs). Bioorg Med Chem Lett 2008; 18: 1011-6.
67. Clarke B, Demont E, Dingwall C, Dunsdon R, Faller A, Hawkins J, et al. BACE-1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character. Bioorg Med Chem Lett 2008; 18: 1017-21.
68. Beswick P, Charrier N, Clarke B, Demont E, Dingwall C, Dunsdon R, et al. BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. Bioorg Med Chem Lett 2008; 18: 1022-6.
69. Cole D, Manas E, Stock J, Condon J, Jennings L, Aulabaugh A, et al. Acylguanidines as small-molecule β-secretase inhibitors. J Med Chem 2006; 49: 6158-61.
70. Cole DC, Stock JR, Chopra R, Cowling R, Ellingboe JW, Fan KY, et al. Acylguanidine inhibitors of [beta]-secretase: Optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett 2008; 18: 1063-6.
71. Jennings LD, Cole DC, Stock JR, Sukhdeo MN, Ellingboe JW, Cowling R, et al. Acylguanidine inhibitors of β-secretase: Optimization of the pyrrole ring substituents extending into the substrate binding pocket. Bioorg Med Chem Lett 2008; 18: 767-71.
72. Fobare WF, Solvibile WR, Robichaud AJ, Malamas MS, Manas E, Turner J, et al. Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg Med Chem Lett 2007; 17: 5353-6.
73. Malamas MS, Barnes K, Hui Y, Johnson M, Lovering F, Condon J, et al. Novel pyrrolyl 2-aminopyridines as potent and selective human β-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 2010; 20: 2068-73.
74. Malamas, M.S., Fobare, W.F., Solvibile, Jr., William, R., Lovering, F.E., Condon, J.S., Robichaud, A.J. Amino-pyridines as inhibitors of β-secretase. US20060173049 (2006).
75. Malamas, M.S., Fobare, W.F., Solvibile, Jr.W.R., Lovering, F.E., Condon, J.S., Robichaud, A.J. Amino-pyridines as inhibitors of β- secretase. US20100204245 (2010).
76. Malamas MS, Barnes K, Johnson M, Hui Y, Zhou P, Turner J, et al. Di-substituted pyridinyl aminohydantoins as potent and highly selective human β-secretase (BACE1) inhibitors. Bioorg Med Chem 2010; 18: 630-9.
77. Gerritz, S., Good, A.C., Thompson III L. A., Zhai, W., Shi, S., Zhu, S. Acyl guanidines as β-secretase inhibitors. US20070015754 (2007).
78. Gerritz, S., Zhai, W., Shi, S., Zhu, S., Good, A.C., Thompson III L.A. Acyl guanidines as β-secretase inhibitors. US20097612069 (2009).
79. Boy, K.M., Zhu, S., Macor, J.E., Shi, S., Gerritz, S. N-aryl pyrrolidine derivatives as β-secretase inhibitors. US20070232679 (2007).
80. Boy, K.M., Zhu, S., Macor, J.E., Shi, S., Gerritz, S. N-aryl pyrrolidine derivatives as β-secretase inhibitors. US20087408071 (2008).
81. Wu, Y.-J., Gerritz, S., Shi, S., Zhu, S. Oxime-containing acyl guanidines as β-secretase inhibitors. US20087390925 (2008).
82. Thompson III L. A., Shi, J., Zusi, C.F., Dee Michael, F., Macor, John E. Indole acetic acid acyl guanidines as β-secretase inhibitors. US20097601751 (2009).
83. Wu, Y.-J., Gerritz, S., Shi, S., Zhu, S. Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors. US20107678784 (2010).
84. Shi, S., Gerritz, S., Zhu, S. Macrocyclic acyl guanidines as β- secretase inhibitors. US20080262055 (2008).
85. Shi, S., Gerritz, S., Zhu, S. Macrocyclic acyl guanidines as β- secretase inhibitors. US20107732434 (2010).
86. Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL, et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (β-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 2007; 50: 4261-4.
87. Baxter, E., Creighton, C.J., Ho, C.Y., Huang, Y., Lu, T., Luo, C., Reitz, A.B., Reynolds, C.H., Ross, T.M., Siber-McMaster, E. 2- Amino-quinoline derivatives useful as inhibitors of β-secretase (BACE). US20090227581 (2009).
88. Huang Y, Strobel ED, Ho CY, Reynolds CH, Conway KA, Piesvaux JA, et al. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads. Bioorg Med Chem Lett 20: 3158-60.
89. Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr R, et al. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase. J Med Chem 2007; 50: 1124-32.
90. Edwards PD, Albert JS, Sylvester M, Aharony D, Andisik D, Callaghan O, et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 2007; 50: 5912-25.
91. Chessari, G., Congreve, M.S., Holenz, J., Murray, C., Patel, S., Rakos, L., Rotticci, D. Pyrrolopiridine derivatives and tehir use as BACE inhibitors. WO2009022961 (2009).
92. Chessari, G., Congreve, M.S., Holenz, J., Murray, C., Patel, S., Rakos, L., Rotticci, D. Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions. US20097629356 (2009).
93. Berg, S., Hogdin, K., Kihlstrom, J., Plobeck, N., Sehgelmeble, F., Wirstam, M. New Compounds 317. US200811761130 (2008).
94. Berg, S., Holenz, J., Hogdin, K., Kihlstrom, J., Kolmodin, K., Lindstrom, J., Plobeck, N., Rotticci, D., Sehgelmeble, F., Wirstam, M. New Compounds 318. US20080058349 (2008).
95. Arnold, J., Edwards, P., Sylvester, M., Berg, S., Holenz, J., Kers, A., Kolmodin, K., Rakos, L., Ohberg, L., Rotticci, D., Chessari, G., Congreeve, M., Murray, C., Patel, S., New Compounds 391. US20080171771 (2008).
96. Rajapakse H, Nantermet P, Selnick H, Munsh iS, McGaughey G, Lindsley S, et al. Discovery of oxadiazoyl tertiary carbinamine inhibitors of β-secretase (BACE-1). J Med Chem 2006; 49: 7270-3.
97. Lindsley S, Moore K, Rajapakse H, Selnick H, Young M, Zhu H, et al. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 2007, 17: 4057-61.
98. Moore KP, Zhu H, Rajapakse HA, McGaughey GB, Colussi D, Price EA, et al. Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 2007; 17: 5831-5.
99. McGaughey GB, Colussi D, Graham SL, Lai M-T, Munshi SK, Nantermet PG, et al. β-Secretase (BACE-1) inhibitors: Accounting for 10s loop flexibility using rigid active sites. Bioorg Med Chem Lett. 2007; 17: 1117-21.
100. Stanton MG, Stauffer SR, Gregro AR, Steinbeiser M, Nantermet P, Sankaranarayanan S, et al. Discovery of isonicotinamide derived β- secretase inhibitors: in vivo Reduction of β-amyloid. J Med Chem 2007; 50: 3431-3.
101. Nantermet PG, Rajapakse HA, Stanton MG, Stauffer SR, Barrow JC, Gregro AR, et al. Evolution of tertiary carbinamine BACE-1 inhibitors: Aβ reduction in rhesus CSF upon oral dosing. Chem Med Chem 2009; 4: 37-40.
102. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, et al. First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 2009; 328: 131-40.
103. Zhu H, Young MB, Nantermet PG, Graham SL, Colussi D, Lai MT, et al. Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg Med Chem Lett 2010; 20: 1779-82.
104. Rajapakse HA, Nantermet PG, Selnick HG, Barrow JC, McGaughey GB, Munshi S, et al. SAR of tertiary carbinamine derived BACE1 inhibitors: Role of aspartate ligand amine pKa in enzyme inhibition. Bioorg Med Chem Lett 2010; 20: 1885-9.
105. Rajapakse H, Nantermet P, Selnick H, Munshi S, McGaughey G, Lindsley S, et al. Discovery of oxadiazoyl tertiary carbinamine inhibitors of β-secretase (BACE-1). J Med Chem 2006; 49: 7270-3.
106. Wang Y-S, Strickland C, Voigt JH, Kennedy ME, Beyer BM, Senior MM, et al. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel μM leads for the development of nM BACE-1 (β-Site APP Cleaving Enzyme 1) inhibitors. J Med Chem 2009; 53: 942-50.
107. Zhu Z, Sun ZY, Ye Y, Voigt J, Strickland C, Smith EM, et al. Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors: Part I-inhibitor design and validation. J Med Chem; 53: 951-65.
108. Godemann R, Madden J, KraÃàmer J, Smith M, Fritz U, Hesterkamp T, et al. Fragment-Based Discovery of BACE1 Inhibitors Using Functional Assays. Biochemistry 2009; 48: 10743-51.
109. Madden J, Dod JR, Godemann R, Kraemer J, Smith M, Biniszkiewicz M, et al. Fragment-based discovery and optimization of BACE1 inhibitors. Bioorg Med Chem Lett 2010; 20: 5329-33.
110. Malamas MS, Erdei J, Gunawan I, Barnes K, Johnson M, Hui Y, et al. Aminoimidazoles as Potent and Selective Human β-ecretase (BACE1) inhibitors. J Med Chem 2009; 52: 6314-23.
111. Malamas, M., Zhou, P., Fobare, W., Solvibile, W., Gunawan, I., Erdei, J.J., Yan, Y., Andrae, P.M., Quagliato, D.A. Amino-5-(5- membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation. WO/2007/005366 (2007).
112. Malamas, M.S., Erdei, J.J., Gunawan, I.S., Zhou, P.Y.Y., Quagliato, D.A. Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase. US20107700602 (2010).
113. Zhou, P., Malamas, M., Li, Y., Robichaud, A., Quagliato, D. Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation. US20070004730 (2007).
114. Quagliato, D.A., Andrae, P.M., Fan, Y. Dihydrospiro[dibenzo [a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of β- secretase. US20097582667 (2009).
115. Malamas, M.S., Barnes, K.D., Johnson, M.R. Imidazole amines as inhibitors of β-secretase. US20080051390 (2008).
116. Nowak P, Cole DC, Aulabaugh A, Bard J, Chopra R, Cowling R, et al. Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 2010; 20: 632-5.
117. Zhou P, Li Y, Fan Y, Wang Z, Chopra R, Olland A, et al. Pyridinyl aminohydantoins as small molecule BACE1 inhibitors. Bioorg Med Chem Lett 2010; 20: 2326-9.
118. Malamas MS, Erdei J, Gunawan I, Turner J, Hu Y, Wagner E, et al. Design and Synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors. J Med Chem 2010; 53: 1146-58.
119. Rogel, O., Rondeau, J.-M., Rueeger, H., Simic, O., Sirockin, F. Tintelnot-Blomley M. Pyrrolidine derivatives useful as BACE inhibitors. US20090247577 (2009).
120. Briard, E., Lueoend, R., Machauer, R., Moebitz, H., Rogel, O., Rondeau, J., Rueger, H., Tintelnot-Blomley, M., Veenstra, S.J. Aminobenzyl substituted cyclic sulfones useful as BACE inhibitors. WO/2009/024615 (2009).
121. Briard, E., Lueoend, R.M., Machauer, R., Moebitz, H., Rogel, O., Rondeau, J.-M., Rueger, H., Tintelnot-Blomley, M., Veenstra, S.J. Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors. 20100056490 (2010).
122. Tamura, Y., Suzuki, S., Tada, Y., Yonezawa, S., Fujikoshi, C., Matsumoto, S., Kooriyama, Y., Ueno, T. Aminodihydrothiazine derivatives substituted with a cyclic group. US20100075957 (2010).
123. Audia, J., Edmund, M.D., James, S.S., Martin, W.B.M. Aminodihydrothiazime derivatives as BACE inhibitors for the treatment of Alzheimer's disease. (2009).
124. Audia, J.E., Mergott, D.J., Sheehan, S.M., Watson, B.M. BACE inhibitors. US20107648983 (2010).
125. White, R., Amegadzie, A., Bryan, M.C., Chen, J.J., Cheng, A.C., Dineen, T., Epstein, O., Gore, V.K., Hua, Z, Human, J.B., Huang, H., Kreiman, C., La, D., Liu, Q., Ma, V.V., Marx, I, Patel, V.F., Qian, W., Weiss, M, Yuan, C. Spiro-tricyclic ring compounds as β- secretase imodulators and methods of use. US20100087429 (2010).
126. Takahashi, H., Fukumoto, H., Maeda, R., Terauchi, J., Kato, K., Miyamoto, M. Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on Aβ peptide levels and impaired learning behavior in aged rats. Brain Res 2010.
127. Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, et al. Efficient inhibition of the Alzheimer's disease β-secretase by membrane targeting. Sci 2008; 320: 520-3.
128. Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 718-26.
129. Holsinger R, McLean, CA, Beyreuther, K, Masters, CL, Evin, G. Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann Neurol 2002; 51: 783-6.
130. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. β-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002; 59: 1381-9.
131. Santosa C, Rasche S, Barakat A, Bellingham SA, Ho M, Tan J, Hill AF, Masters CL, McLean C, Evin G. Decreased expression of GGA3 Protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein. Neurobiol Dis 2011; 43: 176-83.